Skip to content

Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Food Sensitivities (AIRE Study)

Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Non-immune Mediated Food Sensitivities (AIRE Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04309396
Acronym
AIRE
Enrollment
45
Registered
2020-03-16
Start date
2020-10-01
Completion date
2025-03-20
Last updated
2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SIBO, Small Bowel Bacterial Overgrowth Syndrome

Keywords

SIBO

Brief summary

Small intestinal bacterial overgrowth (SIBO) is defined as a condition in which an abnormally high amount of coliform bacteria is present in the small bowel and results in premature anaerobic fermentation of carbohydrates before reaching the colon. Commonly recognized causes include gastric achlorhydria, post-surgical bowel stasis, gastrocolic/coloenteric fistulas, and motility disorders leading to bowel stasis.. The current gold standard for the diagnosis of SIBO, is a breath test that measures the concentration of hydrogen in response to lactulose, a carbohydrate that is only metabolized by bacteria. However, its accuracy is only about 50% and therefore it is not a very useful test, leading most physicians to treat these patients empirically based on clinical suspicion alone. The purpose of this study is to evaluate the clinical utility of a portable medical device called AIRE, an over-the-counter, commercially available handheld breath analyzer that measures exhaled hydrogen content.

Detailed description

Small intestinal bacterial overgrowth (SIBO) is defined as a condition in which an abnormally high amount of coliform bacteria is present in the small bowel and results in premature anaerobic fermentation of carbohydrates before reaching the colon. Commonly recognized causes include gastric achlorhydria (i.e. due to longstanding proton pump inhibitor (PPI) use), post-surgical bowel stasis, and gastrointestinal motility disorders leading to bowel stasis. Although SIBO is commonly suspected, a major limitation in the field is the lack of a highly accurate test for SIBO. The current gold standard relies on the demonstration of an early rise in breath hydrogen concentration in response to an orally ingested carbohydrate (commonly, lactulose) but its accuracy is about 50%. This may be because it is a one-time snapshot with an artificial substrate. Further, it has to be performed in a clinic, takes up to 5 hours and is relatively expensive. The purpose of this study is to evaluate the clinical utility of a portable medical device called AIRE, which is a validated and commercially available handheld breathalyzer that measures hydrogen content in the breath and connects via Bluetooth to an associated smartphone application to provide immediate results and visual feedback after use.

Interventions

DEVICEHydrogen content recording

Eligible participants will eat participants' normal, typical diets during the first week of the study. Participants will use the AIRE machine to measure exhaled H2 content before and after two meals each day - the first meal of the day and the last meal of the day. Participants will breathe into the AIRE machine before eating to obtain a baseline value. Once participants have finished eating, participants will breathe into the AIRE machine 30 minutes, 60 minutes, and 90 minutes postprandially. The participants will record participants' food intake and symptoms directly into participants' smartphone via an app that comes with the AIRE device.

Sponsors

FoodMarble
CollaboratorUNKNOWN
Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (18 years of age or older) * Chronic (\>3 months) GI symptoms such as nausea, bloating, distention, altered bowel movements, weight loss or abdominal pain with no structural cause other than scleroderma. * Clinical diagnosis of SIBO by patient's gastroenterologist with plans to obtain a lactulose hydrogen breath test. * Ability to tolerate oral intake. * Ability to undergo the LHBT. * Access to a smartphone with Bluetooth capability

Exclusion criteria

* History of current or recent antibiotic use within the last 30 days * History of inflammatory bowel disease * Currently following a restrictive diet (for example low Fermentable Oligo-, Di-, Mono-saccharides And Polyols (FODMAP) diet) * Unable to tolerate oral intake

Design outcomes

Primary

MeasureTime frameDescription
Hydrogen Content in Parts Per Million (Ppm)Up to 1 weekExhaled hydrogen (H2) content as measured over a 1-week period by AIRE on the patient's usual diet at home. Mean of one week readings is reported.

Countries

United States

Participant flow

Pre-assignment details

45 participants were enrolled, however 2 patients withdrew for the study before randomization.

Participants by arm

ArmCount
Breath Analyzer
Candidates who, after the screening period are eligible to receive the AIRE device. Hydrogen content recording: Eligible participants will eat participants' normal, typical diets during the first week of the study. Participants will use the AIRE machine to measure exhaled H2 content before and after two meals each day - the first meal of the day and the last meal of the day. Participants will breathe into the AIRE machine before eating to obtain a baseline value. Once participants have finished eating, participants will breathe into the AIRE machine 30 minutes, 60 minutes, and 90 minutes postprandially. The participants will record participants' food intake and symptoms directly into participants' smartphone via an app that comes with the AIRE device.
43
Total43

Baseline characteristics

CharacteristicBreath Analyzer
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
43 Participants
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
36 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 43
other
Total, other adverse events
0 / 43
serious
Total, serious adverse events
0 / 43

Outcome results

Primary

Hydrogen Content in Parts Per Million (Ppm)

Exhaled hydrogen (H2) content as measured over a 1-week period by AIRE on the patient's usual diet at home. Mean of one week readings is reported.

Time frame: Up to 1 week

ArmMeasureValue (MEAN)Dispersion
Breath AnalyzerHydrogen Content in Parts Per Million (Ppm)3.5 ppmStandard Deviation 0.7
Primary

Hydrogen Content in Parts Per Million (Ppm)

For participants who have a positive LHBT test at baseline, antibiotics are prescribed as part of standard of care. These participants will have a repeat AIRE test at 2 weeks post antibiotic treatment.

Time frame: 2 weeks after antibiotic treatment for positive LHBT

Population: Only participants with positive LHBT test at baseline were analyzed.

ArmMeasureValue (MEAN)Dispersion
Breath AnalyzerHydrogen Content in Parts Per Million (Ppm)10.7 ppmStandard Deviation 1.1
Primary

Hydrogen Content in Parts Per Million (Ppm)

For participants who have a negative LHBT test at baseline, a repeat AIRE test is done at 1 month after baseline test.

Time frame: One month after negative LHBT

Population: Only Participants who had a negative LHBT test at baseline were analyzed

ArmMeasureValue (MEAN)Dispersion
Breath AnalyzerHydrogen Content in Parts Per Million (Ppm)8.5 ppmStandard Deviation 3.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026